Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CheckMate 274
2022-500630-29-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in transitional cell carcinoma (TCC) comparing Nivolumab with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Aug 2022; status: completed.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2022-500630-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500630-29-00.